We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-8.67%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.42B
AUM Growth
-$513M
(-10%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
6.32%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
73
New
3
Increased
13
Reduced
2
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVAC
CureVac
CVAC
|
+$107M |
| 2 |
Vaxcyte
PCVX
|
+$60.8M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$53.5M |
| 4 |
Geron
GERN
|
+$52.9M |
| 5 |
Pliant Therapeutics
PLRX
|
+$50.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$83.8M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$52.6M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$25M |
| 4 |
DALS
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
|
+$15M |
| 5 |
Celldex Therapeutics
CLDX
|
+$14.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| 2 | Miscellaneous | 0.01% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITOS
26
DELISTED
iTeos Therapeutics
ITOS
| $60.1M | 1.36% |
4,417,259
| – | – |
|
27
NewAmsterdam Pharma
NAMS
$2.53B
| $53M | 1.2% |
4,000,000
| – | – |
|
28
Viridian Therapeutics
VRDN
$2.47B
| $51.1M | 1.16% |
2,007,946
+1,127,946
| +128% | +$36.2M |
|
29
RxSight
RXST
$234M
| $50.9M | 1.15% |
3,052,796
| – | – |
|
|
30
Mineralys Therapeutics
MLYS
$2.56B
| $49.8M | 1.13% |
+3,178,476
| New | +$53.5M |
|
|
31
Pliant Therapeutics
PLRX
$69.4M
| $46.9M | 1.06% |
+1,762,000
| New | +$50.2M |
|
32
Enliven Therapeutics
ELVN
$3.91B
| $46.5M | 1.05% |
2,122,465
+1,309,784
| +161% | +$26.6M |
|
33
GH Research
GHRS
$1.89B
| $44.6M | 1.01% |
5,581,161
+682,788
| +14% | +$6.28M |
|
34
Acumen Pharmaceuticals
ABOS
$209M
| $39.7M | 0.9% |
9,770,773
| – | – |
|
|
CLYM
35
Climb Bio
CLYM
$799M
| $38.1M | 0.86% |
13,150,849
| – | – |
|
36
AN2 Therapeutics
ANTX
$202M
| $37.2M | 0.84% |
3,773,517
| – | – |
|
|
ALPN
37
DELISTED
Alpine Immune Sciences Inc
ALPN
| $36.2M | 0.82% |
4,688,115
+290,747
| +7% | +$2.32M |
|
38
Aclaris Therapeutics
ACRS
$814M
| $35.6M | 0.81% |
4,398,453
| – | – |
|
|
ICVX
39
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $34.6M | 0.78% |
5,963,565
| – | – |
|
40
Fulcrum Therapeutics
FULC
$288M
| $33.1M | 0.75% |
11,609,704
+2,103,779
| +22% | +$18.8M |
|
|
HLVX
41
DELISTED
HilleVax
HLVX
| $29.1M | 0.66% |
1,760,019
| – | – |
|
42
Nkarta
NKTX
$206M
| $27.7M | 0.63% |
7,805,129
| – | – |
|
|
KNTE
43
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $26.7M | 0.6% |
4,264,144
| – | – |
|
|
NSTG
44
DELISTED
NanoString Technologies, Inc.
NSTG
| $24.3M | 0.55% |
2,457,273
+2,313,373
| +1,608% | +$22.9M |
|
45
ARS Pharmaceuticals
SPRY
$423M
| $19.6M | 0.44% |
3,009,678
| – | – |
|
|
46
Rocket Pharmaceuticals
RCKT
$374M
| $19.4M | 0.44% |
1,131,775
-1,275,374
| -53% | -$25M |
|
47
Tenaya Therapeutics
TNYA
$150M
| $17.3M | 0.39% |
6,067,483
| – | – |
|
48
Design Therapeutics
DSGN
$765M
| $17.1M | 0.39% |
2,971,231
| – | – |
|
49
Solid Biosciences
SLDB
$897M
| $16.2M | 0.37% |
3,426,286
| – | – |
|
50
Werewolf Therapeutics
HOWL
$47.6M
| $16M | 0.36% |
6,144,881
+1,853,000
| +43% | +$5.52M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, RA Capital Management held 73 positions worth $4.42B, down 10% from $4.93B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
RA Capital Management deployed $279M of net new capital in Q1 2023, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was CureVac: 12,245,955 shares worth $85.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $25M trimmed.
- RA Capital Management's largest Q1 2023 buy was CureVac: 12,245,955 shares worth $85.4M.
- RA Capital Management added most to Vaxcyte in Q1 2023, an estimated $60.8M increase.
- RA Capital Management's biggest Q1 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $25M.
- RA Capital Management fully exited Travere Therapeutics in Q1 2023, selling an estimated $83.8M.
- RA Capital Management's ten largest holdings make up 50% of its $4.42B portfolio in Q1 2023.
- RA Capital Management opened 3 new positions and closed 14 in Q1 2023.
- RA Capital Management's portfolio value fell 10% quarter-over-quarter to $4.42B.
Based on RA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.